
The S&P 500 Is Up 7% Year to Date, but These 3 Stocks More Than Doubled That Return So Far. Is It Time to Buy?
Meta's outstanding operating margin is part of the reason why its stock is up 20% year to date.
After years of stagnation, IBM is showing signs of significant growth.
There has seemingly been no limit to Palantir's staggering momentum.
10 stocks we like better than Palantir Technologies ›
The first half of 2025 is in the books -- and it was a roller coaster. Nevertheless, as of this writing, the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are up 7%, 8%, and 5%, respectively.
However, many stocks have put those returns to shame.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Three Motley Fool contributing analysts identified three stocks that have more than doubled the return of the S&P 500 so far this year: Meta Platforms (NASDAQ: META), International Business Machines (NYSE: IBM), and Palantir Technologies (NASDAQ: PLTR).
Is it time to load up on them?
Meta generates roughly $470 million in revenue every day
Jake Lerch (Meta Platforms): As of this writing, shares of Meta Platforms are up 20% year to date, nearly triple the return of the S&P 500 over the same period.
Clearly, Meta is firing on all cylinders, but what is behind its big rally, and will it continue?
To start, Meta's stock is surging because the company's business model continues to prove its worth. Meta has more than 3 billion daily average users across its platforms, like Facebook and Instagram, meaning it can place millions of ads each day, which, in turn, generates a daily average of around $470 million in revenue for the company.
Better still, a tremendous share of Meta's revenue is converted into profit. Indeed, the company's operating margin stands at 43%. For context, many analysts view a margin of 10% to be healthy, while 20% is considered high.
Even within the lofty ranks of the " Magnificent Seven," Meta's margin shines. It ranks third -- behind only Nvidia (the world's largest company by market cap) and Microsoft (the world's second-largest company by market cap).
Turning to its future, Meta appears very well positioned. With so much of the world's population already using its platforms on a daily basis, Meta can afford to invest heavily in new initiatives. It has spent heavily on artificial intelligence (AI) infrastructure, and it now appears ready to unleash the potential of that investment.
The company plans to roll out automated advertising -- powered by AI -- across its platforms by the end of 2026. This could introduce a new lucrative revenue stream for the company, further boosting its already impressive revenue and profit totals.
Meta stock has outperformed the market so far this year, and it may continue to do so thanks to its immense user base, strong margins, and AI-powered innovations.
Investors should not ignore the quiet comeback of this tech giant
Will Healy (International Business Machines): Investors can likely be forgiven for not noticing the comeback in IBM stock.
The venerable tech giant struggled throughout the 2010s as growth in its consulting and tech infrastructure businesses slowed dramatically, and most investors seemed to turn their attention to newer and seemingly more cutting-edge tech companies.
However, its paradigm began to shift when IBM bought cloud giant Red Hat in 2019. Soon after, IBM appointed Arvind Krishna, the executive who drove this purchase, as its CEO in April 2020.
That move enabled IBM to emerge as one of the leaders in the hybrid cloud. Also, with its spinoff of its managed infrastructure business into Kyndryl, it was free to focus more heavily on cloud, AI, and supercomputing enterprises.
With that, investors again began taking notice of the stock, particularly after the end of the 2022 bear market. So profound is its growth that it returned to its previous all-time high in 2024, and its growth has continued. In 2025, the stock is up 30%.
Admittedly, the company has more work to do. In the first quarter of 2025, revenue rose by only 1%. Nonetheless, its software segment, which accounts for all of the company's current growth, was up 7%, signaling that improved growth could be at hand.
Additionally, it approved its 30th consecutive dividend increase earlier this year. At $6.72 per share annually, its dividend yield is around 2.4%, almost double the S&P 500 average of 1.2%. That dividend should make the stock more attractive for income investors.
Indeed, the buy case is more unclear for growth investors considering its 49 P/E ratio. Still, a forward P/E ratio of 26 implies that significant financial improvement is forthcoming, and it appears to be positioned to match the market's performance. That factor likely makes IBM a buy for investors seeking both income and growth.
Palantir Technologies continued to soar, doubling already since January
Justin Pope (Palantir Technologies): Artificial intelligence software is already changing the world, and Palantir Technologies has become the face of that.
The company develops custom software applications for government and corporate clients that utilize a combination of AI, machine learning, and data analytics to address some of the world's most pressing challenges. The company formally launched its AIP platform for AI applications in 2023, and Palantir's growth has continued to accelerate since then.
There are 20,000 large businesses in the United States alone, so Palantir, with fewer than 450 U.S. commercial customers, has a tremendous growth opportunity ahead. That has investors expecting big things in the future, which continues to propel Palantir's stock to great heights. Shares gained 1,600% over the past three years, including a 100% run since the start of 2025.
While you never know how high a stock can go, it's probably not wise to buy here -- Palantir trades at astronomical valuations, which will likely weigh on the stock's future performance.
Analysts estimate Palantir will grow earnings by an average of 31% annually over the long term, which is blistering fast growth. Yet Palantir trades at a forward P/E ratio of 261, versus 22 for the S&P 500, which has historically grown at an annualized rate of approximately 10%.
So, Palantir, anticipated to grow 3 times faster than the S&P 500, is valued nearly 12 times higher? It doesn't make sense. Therefore, it's probably best to avoid chasing this red-hot stock until that ratio comes back to Earth a bit.
Should you invest $1,000 in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jake Lerch has positions in International Business Machines and Nvidia and has the following options: long July 2025 $425 puts on Microsoft. Justin Pope has no position in any of the stocks mentioned. Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends International Business Machines, Kyndryl, Meta Platforms, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
25 minutes ago
- Globe and Mail
Lost Money on Reddit, Inc. (RDDT)? Join Class Action Before August 18, 2025 - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - July 24, 2025) - If you suffered a loss on your Reddit, Inc. (NYSE: RDDT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against Reddit, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 29, 2024 and May 20, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) changes in Google Search's algorithm and features like AI Overview were causing users to stop their query on Google Search; (ii) these algorithm changes were materially different than prior instances of reduced traffic to the Reddit website; (iii) defendants were aware that the increase in the query term "Reddit" on search engines was because users were getting the sought after answer from Google Search without having to go to Reddit, and not because they intended to visit Reddit; (iv) this zero-click search reality was dramatically reducing traffic to Reddit in a manner the Company was unable to overcome in the short term; (v) defendants, therefore, lacked a reasonable basis for their outlook on user rates and advertising revenues; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Reddit, Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.


Globe and Mail
35 minutes ago
- Globe and Mail
CRH Announces Date for Q2 2025 Results Conference Call
CRH (NYSE: CRH), the leading provider of building materials solutions, will publish its Q2 2025 financial results after market close on Wednesday, August 6, 2025 followed by a conference call and webcast presentation at 8:00 a.m. (EDT) on Thursday, August 7, 2025. CRH's results and the related presentation will be available at Registration for the event can be made at Upon registration a link to join the call and dial-in details will be made available. A replay of the webcast will be available on About CRH CRH (NYSE: CRH) is the leading provider of building materials solutions that build, connect and improve our world. Employing 80,000 people at over 3,800 operating locations in 28 countries, CRH has market leadership positions in North America and Europe. As the essential partner for transportation and critical infrastructure projects, complex non-residential construction and outdoor living solutions, CRH's unique offering of materials, products and value-added services helps to deliver a more resilient and sustainable built environment. The company is ranked among sector leaders by Environmental, Social and Governance (ESG) rating agencies. A Fortune Global 500 company, CRH's shares are listed on the NYSE and LSE.

National Post
36 minutes ago
- National Post
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk--Long Before the Clinic
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. Article content 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENS ai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Article content Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. Article content LENS ai 's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Article content Study Highlights Article content 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Article content Read the full case study: Article content [ Article content link Article content ] Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Article content Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Article content Article content Article content Article content Contacts Article content Investor Relations Contact Article content Article content Article content Article content